New evidence on pitavastatin: Efficacy and safety in clinical studies

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 5, 2010, Pages 817-828

  Teramoto, Tamio ^a   Shimano, Hitoshi ^b   Yokote, Koutaro ^c   Urashima, Mitsuyoshi ^d  

^a TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

^c CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cardiovascular disease; Chronic kidney disease; Diabetes mellitus; High density lipoprotein cholesterol; Low density lipoprotein cholesterol; Safety; Statins

Indexed keywords

ANTIDIABETIC AGENT; ATORVASTATIN; CYCLOSPORIN; ERYTHROMYCIN; FLUINDOSTATIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PITAVASTATIN; PLACEBO; PRAVASTATIN; SIMVASTATIN;

ACUTE CORONARY SYNDROME; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CREATINE KINASE BLOOD LEVEL; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLOMERULUS FILTRATION RATE; GLUCOSE INTOLERANCE; GLUCOSE TRANSPORT; GLYCEMIC CONTROL; HEPATOBILIARY DISEASE; HUMAN; HYPERCHOLESTEROLEMIA; INCIDENCE; LIPID BLOOD LEVEL; MYALGIA; MYOPATHY; OBESITY; POSTMARKETING SURVEILLANCE; PROTEIN BINDING; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; TIME TO MAXIMUM PLASMA CONCENTRATION; URINARY EXCRETION;

ANIMALS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CLINICAL TRIALS AS TOPIC; GLOMERULAR FILTRATION RATE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; PRACTICE GUIDELINES AS TOPIC; PYRROLES; QUINOLINES;

EID: 77949479227     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656561003641990     Document Type: Review

References (53)

1. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease; the Scandinavian simvastatin survival study (4S). Lancet 1994;344:1383-1389
2. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-1307
3. Nakamura H, Arakawa K, Itakura H, et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA study): a prospective randomized controlled trial. Lancet 2006;368:1155-1163
4. Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006;295:1556-1565
5. Takayama T, Hiro T, Yamagishi M, et al. Effect of rosuvastatin on coronary atheroma in stable coronary artery disease. Circ J 2009;73:2110-2117
6. Chapman MJ. Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease. Pharmacol Ther 2006;111:893-908
7. Shepherd J, Kastelein JJ, Bittner V, et al. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. Clin J Am Soc Nephrol 2007;2:1131-1139
8. Freeman DJ, Norrie J, Sattar N, et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001;103:357-362
9. Scirica BM, Morrow DA, Cannon CP. Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study. J Am Coll Cardiol 2006;47:2326-2331
10. Hayashi T, Yokote K, Saito Y. Pitavastatin: efficacy and safety in intensive lipid lowering. Expert Opin Pharmacother 2007;8:2315-2327
11. Aoki T, Nishimura H, Nakagawa S, et al. Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Arzneimittelforschung 1997;47:904-909
12. Morikawa S, Umetani M, Nakagawa S, et al. Relative induction of mRNA for HMG CoA reductase and LDL receptor by five different HMG-CoA reductase inhibitors in cultured human cells. J Atheroscler Thromb 2000;7:138-144
13. Saito Y, Yamada N, Teramoto T, et al. A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia. Atherosclerosis 2002;162:373-379
14. Teramoto T, Saito Y, Yamada N, et al. Clinical safety and efficacy of NK-104 (Pitavastatin), a new synthetic HMG-CoA reductase inhibitor, in the long-term treatment of hyperlipidemia. Results of a multicenter long-term study [in Japanese with English abstract]. J Clin Ther Med 2001;17:885-914
15. Sone H, Takahashi A, Shimano H, et al. HMG-CoA reductase inhibitor decreases small dense low-density lipoprotein and remnant-like particle cholesterol in patients with type-2 diabetes. Life Sci 2002;71:2403-2412
16. Noji Y, Higashikata T, Inazu A, et al. Long-term treatment with pitavastatin (NK-104), a new HMG-CoA reductase inhibitor, of patients with heterozygous familial hypercholesterolemia. Atherosclerosis 2002;163:157-164
17. Ouchi Y, Saito Y, Ito H, et al. Efficacy and safety of NK-104 (pitavastatin), a new HMG-CoA reductase inhibitor in the elderly patients with hyperlipidemia [in Japanese with English abstract]. Geriatr Med 2001;39:849-860
18. Kajinami K, Takekoshi N, Saito Y. Pitavastatin: efficacy and safety profiles of a novel synthetic HMG-CoA reductase inhibitor. Cardiovasc Drug Rev 2003;21:199-215
19. Fujino H, Saito T, Tsunenari Y, et al. Metabolic properties of the acid and lactone forms of HMG-CoA reductase inhibitors. Xenobiotica 2004;34:961-971
20. Fujino H, Saito T, Tsunenari Y, et al. Interaction between several medicines and statins. Arzneimittelforschung 2003;53:145-153
21. Kurihara Y, Douzono T, Kawakita K, et al. A large-scale, long-term, prospective post-marketing surveillance of pitavastatin (LIVALO tablet)-LIVALO effectiveness and safety (LIVES) study. Jpn Pharmacol Ther 2008;36:709-731
22. Teramoto T, Sasaki J, Ueshima H, et al. Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese. J Atheroscler Thromb 2007;14:45-50
23. Teramoto T, Shimano H, Yokote K, et al. Effects of pitavastatin (LIVALO tablet) on high density lipoprotein cholesterol (HDL-C) in hypercholesterolemia sub-analysis of LIVALO effectiveness and safety (LIVES) study. J Atheroscler Thromb 2009;16:654-661
24. Kimura K, Shimano H, Yokote K, et al. Effects of pitavastatin (LIVALO tablet) on the estimated glomerular filtration rate (eGFR) in hypercholesterolemic patients with chronic kidney disease-sub-analysis of the LIVALO effectiveness and safety (LIVES) study. J Atheroscler Thromb (In press)
25. Okazaki S, Yokoyama T, Miyauchi K, et al. Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH study. Circulation 2004;110:1061-1068
26. Hiro T, Kimura T, Morimoto T, et al. Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome] study). J Am Coll Cardiol 2009;54:293-302
27. Robinson JG, Wang S, Smith BJ, et al. Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk. J Am Coll Cardiol 2009;53:316-322
28. Rosenson RS. Management of non-high-density lipoprotein abnormalities. Atherosclerosis 2009;207:328-335
29. Yokote K, Bujo H, Hanaoka H, et al. Multicenter collaborative randomized parallel group comparative study of pitavastatin and atorvastatin in Japanese hypercholesterolemic patients: collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study). Atherosclerosis 2008;201:345-352
30. Yokote K, Saito Y; CHIBA Study Investigators. Influence of statins on glucose tolerance in patients with Type 2 diabetes mellitus: subanalysis of the collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study). J Atheroscler Thromb 2009;16:297-298
31. Sasaki J, Ikeda Y, Kuribayashi T, et al. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance. Clin Ther 2008;30:1089-1101
32. Budinski D, Arneson V, Hounslow N, et al. Piatavastatin compared with atorvastatin in primary hypercholestelemia or combined dyslipidemia. Clin Lipidol 2009;4:291-302
33. Ose L, Budinski D, Hounslow N. Comparison of pitavastatin with simvastatin in primary hypercholesterolaemia or combined dyslipidaemia. Curr Med Res Opin 2009;25:2755-2764
34. National Cholesterol Education Program. Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel II). Circulation 1994;89:1333-1445
35. Nakamura Y, Yamamoto T, Okamura T, et al. Combined cardiovascular risk factors and outcome: NIPPON DATA80, 1980-1994. Circ J 2006;70:960-964
36. Cannon CP, Dansky HM, Davidson M. Design of the DEFINE trial: determining the efficacy and tolerability of CETP inhibition with anacetrapib. Am Heart J 2009;158:513-19.e3
37. Wolk R, Chen D, Clark RW, et al. Pharmacokinetic, pharmacodynamic, and safety profile of a new cholesteryl ester transfer protein inhibitor in healthy human subjects. Clin Pharmacol Ther 2009;86:430-437
38. Okamura T, Hayakawa T, Kadowaki T, et al. The inverse relationship between serum high-density lipoprotein cholesterol level and all-cause mortality in a 9.6-year follow-up study in the Japanese general population. Atherosclerosis 2006;184:143-150
39. Kitamura A, Iso H, Naito Y, et al. High-density lipoprotein cholesterol and premature coronary heart disease in urban Japanese men. Circulation 1994;89:2533-2539
40. Ando H, Tsuruoka S, Yanagihara H, et al. Effects of grapefruit juice on the pharmacokinetics of pitavastatin and atorvastatin. Br J Clin Pharmacol 2005;60:494-497
41. Hirano M, Maeda K, Shitara Y, et al. Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab Dispos 2006;34:1229-1236
42. Rajpathak SN, Kumbhani DJ, Crandall J, et al. Statin therapy and risk of developing Type 2 diabetes: a meta-analysis. Diabetes Care 2009;32:1924-1929
43. Yamakawa T, Takano T, Tanaka S, et al. Influence of pitavastatin on glucose tolerance in patients with Type 2 diabetes mellitus. J Atheroscler Thromb 2008;15:269-275
44. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-2207
45. Nakata M, Nagasaka S, Kusaka I, et al. Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control. Diabetologia 2006;49:1881-1892
46. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension 2003;42:1050-1065
47. Liang XM, Otani H, Zhou Q, et al. Renal protective effects of pitavastatin on spontaneously hypercholesterolaemic Imai Rats. Nephrol Dial Transplant 2007;22:2156-2164
48. Nakamura T, Sugaya T, Kawagoe Y, et al. Effect of pitavastatin on urinary liver-type fatty acid-binding protein levels in patients with early diabetic nephropathy. Diabetes Care 2005;28:2728-2732
49. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-1504
50. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in Type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-696
51. Nasu K, Tsuchikane E, Katoh O, et al. Accuracy of in vivo coronary plaque morphology assessment: a validation study of in vivo virtual histology compared with in vitro histopathology. J Am Coll Cardiol 2006;47:2405-2412
52. Nasu K, Tsuchikane E, Katoh O, et al. Effect of fluvastatin on progression of coronary atherosclerotic plaque evaluated by virtual histology intravascular ultrasound. JACC Cardiovasc Interv 2009;2:689-696
53. Toi T, Taguchi I, Yoneda S, et al. Early effect of lipid-lowering therapy with pitavastatin on regression of coronary atherosclerotic plaque. Comparison with atorvastatin. Circ J 2009;73:1466-1472